Sponsors are still not where they should be on meeting postmarket trial requirements and commitments, the FDA’s latest analysis shows: 24 percent of annual status reports for required or agreed…
Shionogi’s investigative COVID-19 therapy is showing some promise in early laboratory studies, rapidly clearing viral levels and decreasing the period of active shedding, the company reported at the European Congress…
A large postmarket study suggests that some patients with multiple sclerosis (MS) who are stable on Biogen’s Tysabri (natalizumab) can safely extend their dosing interval from four to six weeks.…
The European Medicines Agency (EMA) has issued a final guidance for drug developers on the quality data needed to support applications to its Priority Medicines (PRIME) program and other unmet…
India is making moves to reduce its dependence on countries like China for sourcing active pharmaceutical ingredients (API) used in manufacturing regulated medicines. Source: Drug Industry Daily
The FDA has expanded its approval of Gilead Sciences’ Veklury (remdesivir) for pediatric patients 28 days and older weighing at least 6.6 pounds who have tested positive for COVID-19 and…
Ardelyx said the FDA will convene an advisory committee meeting to review the company’s Xphozah (tenapanor) as a treatment for the control of serum phosphorus in adults suffering from chronic…
Roche’s breast cancer drug candidate giredestrant, an oral selective estrogen receptor degrader (SERD), didn’t meets its primary endpoint of progression-free survival in a phase 2 trial of patients with an…
Axsome Therapeutics said it anticipates the FDA will decline to approve its experimental drug AXS-07 for the acute treatment of migraines because of problems related to its chemistry, manufacturing and…
The European Medicines Agency’s (EMA) human safety medicines committee signed off on four new drugs during its monthly meeting held from April 19 to 22, including Novartis’ (capmatinib) for treating…